Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1677
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2490
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    51,187.53
    -436.18 (-0.84%)
     
  • CMC Crypto 200

    1,326.95
    -69.58 (-4.99%)
     
  • S&P 500

    5,112.31
    +63.89 (+1.27%)
     
  • DOW

    38,325.52
    +239.72 (+0.63%)
     
  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     
  • GOLD FUTURES

    2,347.40
    +4.90 (+0.21%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Why This FDA Approval Is a Game Changer for Eli Lilly

Why This FDA Approval Is a Game Changer for Eli Lilly

Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.